434 related articles for article (PubMed ID: 35551369)
1. Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies.
Lerario AM; Mohan DR; Hammer GD
Endocr Rev; 2022 Nov; 43(6):1051-1073. PubMed ID: 35551369
[TBL] [Abstract][Full Text] [Related]
2. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
3. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
4. Surgical management of adrenocortical carcinoma.
Ranvier GG; Inabnet WB
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
[TBL] [Abstract][Full Text] [Related]
5. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
6. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
7. Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
Kenney L; Hughes M
Surg Oncol Clin N Am; 2023 Apr; 32(2):279-287. PubMed ID: 36925185
[TBL] [Abstract][Full Text] [Related]
8. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for adrenocortical carcinoma.
Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
[TBL] [Abstract][Full Text] [Related]
10. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
11. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.
Ronchi CL; Sbiera S; Volante M; Steinhauer S; Scott-Wild V; Altieri B; Kroiss M; Bala M; Papotti M; Deutschbein T; Terzolo M; Fassnacht M; Allolio B
PLoS One; 2014; 9(8):e105855. PubMed ID: 25144458
[TBL] [Abstract][Full Text] [Related]
12. Pediatric adrenocortical carcinoma.
Ilanchezhian M; Varghese DG; Glod JW; Reilly KM; Widemann BC; Pommier Y; Kaplan RN; Del Rivero J
Front Endocrinol (Lausanne); 2022; 13():961650. PubMed ID: 36387865
[TBL] [Abstract][Full Text] [Related]
13. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
14. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
Veytsman I; Nieman L; Fojo T
J Clin Oncol; 2009 Sep; 27(27):4619-29. PubMed ID: 19667279
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers and targeted therapies for adrenocortical carcinoma.
Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
[TBL] [Abstract][Full Text] [Related]
16. The next generation of therapies for adrenocortical cancers.
Kirschner LS
Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
[TBL] [Abstract][Full Text] [Related]
17. Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
Szkodziak PR; Czuczwar P; Woźniak S; Szkodziak F; Paszkowski T
Ginekol Pol; 2017; 88(10):576-577. PubMed ID: 29192420
[TBL] [Abstract][Full Text] [Related]
18. Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer.
Loewe R; Rogowski-Lehmann N; Pfluger T; Reincke M; Hahner S; Bluemel C; Fassnacht M; Beuschlein F
Horm Metab Res; 2021 Jan; 53(1):24-31. PubMed ID: 33086388
[TBL] [Abstract][Full Text] [Related]
19. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
20. Current Status and Future Targeted Therapy in Adrenocortical Cancer.
Alyateem G; Nilubol N
Front Endocrinol (Lausanne); 2021; 12():613248. PubMed ID: 33732213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
